E AND others have previously reported that hCG displayed a weak activity to inhibit the binding of [1251] bovine TSH ([1251] bTSH) to human thyroid membranes, but was unable to produce any significant stimulation of the CAMP response in such membrane preparations (1, 2). In other systems using thyroid tissue or cells of nonhuman origin, on the other hand, hCG has readily been identified as a thyroid stimulator of considerable potency (3) (4) (5) . The failure to demonstrate a thyrotropic activity of hCG in human thyroid preparations in vitro may be due to species variations in the thyroid response to hCG or to a lack of sensitivity of the assay systems used. The affinity of hCG for TSH receptor (TSHr) can be enhanced by desialylation of the molecule, which transforms the hormone into a more potent agonist in FRTL-5 thyroid cells and a strong TSH antagonist in human thyroid membranes (6-9).
Following the successful cloning of the human TSH (hTSH) receptor, it became possible to study both the direct Munich (Fig. 1) . Of the hCG forms, intact hCG displayed little activity to inhibit ['251]bTSH binding, with 100 mg/L (2.6 X low6 mol/L) effecting only approximately 20% inhibition. Asialo-hCG, on the other hand, proved much more potent in this respect, with only 8 mg/L (2.3 X 10e7 mol/L) being required for half-maximum inhibition of [iz51]bTSH binding and 100 mg/L (2.9 X 1O-6 mol/L) producing nearly complete binding inhibition (Fig. 1) not achieved with the highest dose used (Fig. 1) .
To further elucidate the mechanism of bTSH binding inhibition by the hCG forms, experiments were conducted to study the saturation kinetics of bTSH binding in the absence and presence of the inhibitor (Fig. 2) . As indicated by Scatchard plotting and computer-assisted curve fitting of the data obtained with bTSH alone, two apparent binding sites for bTSH were present in HTC-TSHr cells, one of high affinity (-7 x 10-l' mol/L) and relatively low capacity (B,,,, 3 X lo-'* mol/L; -1 fmo1/10,000 cells) and the other of lower affinity (-1 X 10m7 mol/L) and higher capacity (B,,,, 9 X lo-*' mol/L; -300 fmol/lO,OOO cells). The wild-type cells, on the other hand, exhibited only the low affinity TSHbinding sites, which are apparently unrelated to TSHr. Analysis of bTSH binding to HTC-TSHr cells in the presence of fixed concentrations (2 and 4 mg/L; -0.5 and 1 X low7 mol/L) of hCG or asialo-hCG revealed the former to be inactive, but the latter to be a competitive inhibitor at the high affinity sites (Fig. 2) . In another experiment, similar to the one depicted in Fig. 2 , the concentration of hCG was increased to 66 mg/L (1.7 x 10V6 mol/L), which resulted in no significant change in the curve compared to the bTSH curve alone, and that of asialo-hCG to 8 mg/L (2.3 X 10P7 mol/L), which resulted in a nearly complete ablation of high affinity bTSH binding.
The (Fig. 3) .
CAMP production in HTC and HTC-TSHr cells bTSH stimulated intracellular CAMP production in HTCTSHr cells in a dose-dependent fashion, and 10 IU/L bTSH increased basal CAMP levels approximately 9-fold (Fig. 4) Unlike bTSH, both hCG and asialohCG, when added to the transfected cells in concentrations up to 100 mg/L (2.6 and 2.9 X 10e6 mol/L, respectively), were ineffective in significantly increasing basal CAMP production (Fig. 4) . This was also true for the control cells (data not shown).
Next, we examined the effect of hCG and its desialylated variant on bTSH-stimulated CAMP production in HTC-TSHr cells. In the presence of bTSH alone (0.5 IU/L), CAMP production was stimulated approximately 5-fold. Although the addition of intact hCG (up to 400 mg/L; 1.1 X 10P5 mol/ L) did not significantly affect the CAMP response to bTSH, asialo-hCG, added in increasing concentrations from 10 mg/ L (2.9 X 10m7 mol/L) to 200 mg/L (5.7 X 10m6 mol/L), showed a dose-dependent inhibition of bTSH-stimulated CAMP production (Fig. 5) decrease (40% inhibition at 200 mg/L; 5.7 X 10e6 mol/L), indicating a competitive mode of action of the inhibitor.
Discussion
Interest in studies of the thyrotropic activity of hCG originates from its putative roles as the thyroid stimulator responsible for thyroid hyperfunction associated with trophoblastic tumors and a regulator of maternal thyroid function during normal pregnancy (21-29). The question of whether hCG is indeed a thyroid stimulator of significant potency in man is, however, still discussed controversially, and evidence both in favor and against this view has been reported (30) (31) (32) (33) (34) (35) . In the present studies we have undertaken to investigate the interaction of hCG with recombinant hTSHr, exploring its ability to both inhibit the binding of ['251] by hCG of low affinity TSH-binding sites, which has been reported to be unrelated to TSHr and unaccompanied by a CAMP effect (36-38). These findings are entirely consistent with the data that have previously been reported using human thyroid membranes (1, 2). They are, however, at variance with our own data and the findings of others that have been obtained in 12, 39) . Tomer et al. (12) and Yoshimura and co-workers (39), who studied expression of the hTSHr cDNA in CHO cells, showed a dose-related CAMP stimulation in response to purified hCG. With 9.6 X lop7 mol/L hCG causing a definitive increase in CAMP and 100 IU hCG producing a CAMP stimulation equivalent to 9.2 PU recombinant hTSH, as reported by these researchers, the thyroid-stimulating potency of hCG in CHO-TSHr cells resembled that previously calculated using FRTL-5 thyroid cells, but exceeded by far the thyrotropic activity of hCG displayed in human thyroid membranes (1, 4, 6, 12, 26, 39 The striking discrepancies in the thyrotropic activity of hCG depending on the assay system used are difficult to explain. Species variation in the thyroid response to hCG, similar to that observed with other thyroid stimulators, such as Graves' immunoglobulins (40), could be one possible explanation, as has been suggested by some researchers (3). Further, FRTL-5 and CHO-TSHr cells appear to be generally more sensitive to stimulation by TSH than the HTC-TSHr cells used in the present work (4-6, 11, 12, 17, 39) . In this respect, bTSH evoked a significant response in concentrations of 12.3-37 mIU/L in the CHO-TSHr cells used by Yoshimura et al. (39) compared to 50-100 mIU/L required in HTC-TSHr cells. However, even among CHO cell clones expressing the recombinant hTSHr, TSH sensitivity has been reported to vary widely (41). Apart from the fact that different TSH preparations and conditions were used for stimulation of these cells, the main difference between the cell lines expressing recombinant hTSHr is the number of receptors per cell. Whereas Rapoport's (36) CHO-TSHr cells express approximately lo5 TSHr/cell, CHO-TSHr cells transfected by the group of Vassart (41,42) express between 2,000 (clone JP 26) and 90,000 (clone JP 09) receptors per cell. The HTCTSHr cells used in the present studies express approximately 2,300 receptors/cells, which is in the same range as that of human thyroid cells (17, 43) . Thus, it is conceivable that the stimulatory effect of hCG on cAMP generation in CHOTSHr cells may be at least in part due to a supraphysiological number of TSHr expressed by these cells (12, 39) .
Desialylation of the hCG molecule resulted in a marked increase in the affinity of the hormone to recombinant hTSHr, and asialo-hCG achieved a half-maximum inhibition of [1251] bTSH tracer binding at a concentration of 8 mg/L. Its inhibitory constant (Ki) was calculated to be approximately 8 x 10m8 mol/L on the basis of analysis of saturation kinetics in the presence of variable doses of TSH and a fixed concentration of asialo-hCG. Furthermore, radioactively labeled asialo-hCG was shown to specifically bind to recombinant hTSHr, and this binding was displaceable by bTSH. Although desialylated hCG has long been known to interfere with various TSH actions in human thyroid membranes (2, 7-9), this report adds strong evidence that asialo-hCG interacts directly with TSHr. Thus, asialo-hCG seems to be truly an antagonist of the hTSHr, because functionally it inhibited bTSH-stimulated adenylate cyclase activity, but was devoid of intrinsic activity in HTC-TSHr cells. Its mechanism of inhibition appears to be competitive in nature, as has been noted previously and demonstrated here again in its direct interaction with recombinant hTSHr (2, 7). Information on the interaction of desialylated hCG variants with hTSHr may be particularly relevant in the consideration of such substances as possible TSH receptor blockers in the study and treatment of Graves' disease. In this respect, asialo-hCG, owing to its short plasma half-life, would be available mainly for in vitro experiments, whereas other desialylated hCG variants, such as asialoagalacto-hCG, may be suitable for in vim use as an experimental TSHr blocker (9).
